The consequences of drug misuse on post-marketing surveillance
Over the past decade, the ‘traditional’ drug scenario has shown significant changes because of the emergence of a range of molecules, e.g. the novel psychoactive substances (NPS), which are either already existing or newly created molecules [1]. A range of prescribed medications are currently being used as NPS [1]. Overall, the misuse and diversion of medications is a significant and increasing public health concern [2], with 5.4% of British respondents aged 16–19 years old having abused a prescription drug in the past 12 months [3]. It is a matter of concern that, for a range of prescribing molecules (e.g. gabapentinoids), the formal pre-marketing processes had not been able to appropriately identify their potential for abuse, a potential which has however emerged overtime [4,5]. Similarly, drugs such as benzodiazepines and z-hypnotics were considered ‘safe’ for many years before their addictive liability levels were identified. Hence, in this article, we aimed at commenting on the different factors relating to pre- and post-marketing prescription drugs’ abuse liability assessment; issues likely to be complicated by recent changes in drug scenarios.
Item Type | Article |
---|---|
Additional information | Fabrizio Schifano, Gabriele Duccio Papanti, Laura Orsolini & John Martin Corkery, Editorial, 'The consequences of drug misuse on post-marketing surveillance', Expert Review of Clinical Pharmacology, Vol. 9 (7): 867-871, April 2016, doi: http://dx.doi.org/10.1080/17512433.2016.1178571. Published by Taylor & Francis. |
Keywords | pharmacovigilance, addiction, drug misuse, addictive liability, novel psychoactive substances, prescription drugs, prescribing medications |
Date Deposited | 15 May 2025 13:09 |
Last Modified | 31 May 2025 00:05 |
-
picture_as_pdf - The_consequences_of_drug_misuse_on_post_marketing_surveillance_PDF.pdf
-
subject - Published Version
-
lock - Restricted to Repository staff only